Satsuma Pharmaceuticals Announces Three Abstracts Accepted at The 75th American Academy of Neurology Annual Meeting

April 21, 2023

https://www.globenewswire.com/news-release/2023/04/21/2651873/0/en/Satsuma-Pharmaceuticals-Announces-Three-Abstracts-Accepted-at-The-75th-American-Academy-of-Neurology-Annual-Meeting.html

SOUTH SAN FRANCISCO, Calif., April 21, 2023 (GLOBE NEWSWIRE) — Satsuma Pharmaceuticals, Inc. (Nasdaq:STSA), a development-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced that three abstracts highlighting STS101 were accepted at the American Academy of Neurology’s (AAN) 75th Annual Meeting. The 2023 meeting will be held in a hybrid virtual and in-person format in Boston, Massachusetts from Saturday, April 22 to Thursday, April 27, 2023. Full abstracts are now available on the AAN website.

Read more at globenewswire.com

Related news for (STSA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.